| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
Purity: ≥98%
Fenticonazole is an azole class of antifungal drug used locally as the nitrate form for the treatment of vulvovaginal candidiasis. It is a 14-α demethylase inhibitor and potentially a glucosamine-6-phosphate synthase inhibitor. It is active against a range of organisms including dermatophyte pathogens, Malassezia furfur, and Candida albicans. Application of fenticonazole nitrate 1 g intravaginal ovules on 2 alternate days is a suitable first-line treatment of vulvovaginitis with acceptable broad-spectrum efficacy against the most commonly involved pathogens and with a low rate of early relapse, reserving antibiotics for patients with treatment failure or relapse of infection .
| Targets |
Fungal 14α-demethylase [1][2]
|
|---|---|
| ln Vitro |
Fenticonazole is an azole antifungal medication that is applied topically as a nitrate to treat vaginal candidiasis. Malassezia furfur, Candida albicans, and dermatophyte infections are only a few of the species it is effective against [2].
Antifungal activity against Candida albicans: Fenticonazole Nitrate (free drug) showed minimum inhibitory concentration (MIC) of 0.25 μg/mL and minimum fungicidal concentration (MFC) of 0.5 μg/mL against Candida albicans ATCC 10231 [1] - Antifungal activity of terpesomes-loaded Fenticonazole Nitrate: The optimized terpesomes formulation exhibited enhanced antifungal activity, with MIC = 0.0625 μg/mL and MFC = 0.125 μg/mL against Candida albicans ATCC 10231, which was 4-fold more potent than free Fenticonazole Nitrate [1] - In vitro drug release: In pH 4.5 phosphate buffer (mimicking vaginal fluid), terpesomes-loaded Fenticonazole Nitrate showed sustained release, with ~78% cumulative release at 24 h and ~92% at 48 h; free Fenticonazole Nitrate released ~95% within 8 h [1] - Ex vivo vaginal mucosa permeation: Terpesomes-loaded Fenticonazole Nitrate exhibited higher permeation across porcine vaginal mucosa compared to free drug and conventional liposomes: cumulative permeation at 24 h was 68.5 ± 4.2 μg/cm² (terpesomes), 32.1 ± 3.5 μg/cm² (free drug), and 45.3 ± 3.8 μg/cm² (conventional liposomes) [1] - Cytotoxicity on vaginal epithelial cells: Fenticonazole Nitrate (free or terpesomes-loaded, 0.1-10 μg/mL) showed no significant cytotoxicity on VK2/E6E7 human vaginal epithelial cells, with cell viability > 85% after 24 h incubation (MTT assay) [1] |
| ln Vivo |
Efficacy in rat vaginal candidiasis model: Intravaginal administration of terpesomes-loaded Fenticonazole Nitrate (1 mg/kg, once daily for 3 days) resulted in 100% fungal clearance rate in infected rats, compared to 60% for free Fenticonazole Nitrate and 70% for conventional liposome formulation (culturing of vaginal swabs) [1]
- Reduction of vaginal inflammation: Terpesomes-loaded Fenticonazole Nitrate significantly reduced vaginal mucosal inflammation (histopathological analysis) in infected rats: inflammatory cell infiltration was reduced by ~80% compared to untreated control, which was more effective than free drug (~55% reduction) [1] - Clinical efficacy in vulvovaginal candidiasis patients: A 2-day regimen of Fenticonazole Nitrate 1-gram ovules (once daily for 2 days) achieved a clinical cure rate of 92.3% and mycological cure rate of 89.7% at day 7 post-treatment; 87.5% of patients reported complete resolution of pruritus, burning, and discharge symptoms [2] - Sustained efficacy: At day 21 post-treatment, the recurrence rate in Fenticonazole Nitrate-treated patients was 4.2%, which was lower than the historical recurrence rate of 10-15% with standard 3-7 day regimens [2] |
| Cell Assay |
Candida albicans proliferation inhibition assay: Candida albicans ATCC 10231 was cultured in Sabouraud dextrose broth at 37°C for 24 h to prepare a fungal suspension (1×105 CFU/mL). Serial dilutions of free Fenticonazole Nitrate or terpesomes-loaded formulation (0.0156-4 μg/mL) were mixed with the fungal suspension, incubated at 37°C for 48 h. MIC was defined as the lowest concentration inhibiting visible growth; MFC was determined by subculturing on drug-free agar and counting viable colonies [1]
- Vaginal epithelial cell cytotoxicity assay: VK2/E6E7 cells were seeded in 96-well plates (5×103 cells/well) and cultured overnight (37°C, 5% CO2). Cells were treated with free Fenticonazole Nitrate or terpesomes-loaded formulation (0.1-10 μg/mL) for 24 h. MTT reagent was added, incubated for 4 h, formazan crystals were dissolved in DMSO, and absorbance was measured at 570 nm to calculate cell viability [1] |
| Animal Protocol |
Rat vaginal candidiasis model establishment: Female Wistar rats (200-220 g) were ovariectomized to induce pseudoestrus, then intravaginally inoculated with Candida albicans ATCC 10231 suspension (1×106 CFU/rat) to establish infection. Infection was confirmed by positive fungal culture of vaginal swabs 48 h post-inoculation [1]
- Drug administration: Infected rats were randomly divided into 4 groups (n=6/group): terpesomes-loaded Fenticonazole Nitrate (1 mg/kg), free Fenticonazole Nitrate (1 mg/kg), conventional liposomes (1 mg/kg), and untreated control. All formulations were administered intravaginally once daily for 3 consecutive days [1] - Sample collection and evaluation: Vaginal swabs were collected 72 h post-last dose for fungal culture (to determine clearance rate). Rats were euthanized, and vaginal tissues were excised for histopathological analysis of inflammation [1] |
| Toxicity/Toxicokinetics |
In vitro vaginal mucosal irritation: No significant irritation was observed in porcine vaginal mucosa 24 hours after treatment with terpenoids loaded with fenteconazole nitrate (1 mg/mL) (histopathological score: 0.8 ± 0.3), which was comparable to that of the free drug (1.0 ± 0.4) and below the irritation threshold (score > 2) [1]
- Clinical adverse reactions: In a 2-day clinical study, only 3.8% of patients reported mild local adverse reactions (transient pruritus, burning sensation), which resolved spontaneously without treatment; no systemic adverse reactions were observed [2] - No significant abnormalities in body weight or organs were observed in rats treated with terpenoids loaded with fenteconazole nitrate (1 mg/kg, vaginal administration, 3 days) [1] |
| References |
|
| Additional Infomation |
Fenticonazole nitrate is a racemic mixture composed of equimolar amounts of (R)- and (S)-fenteconazole nitrates. It is used to treat vaginal candidiasis. It is an antifungal drug. It is a racemic mixture belonging to the imidazole and fenteconazole classes of antifungal drugs. It contains (S)-fenteconazole nitrate and (R)-fenteconazole nitrate.
Fenticonazole nitrate is an imidazole antifungal drug primarily used to treat vulvovaginal candidiasis[1][2] - Its antifungal mechanism involves the inhibition of fungal 14α-demethylase (a key enzyme in ergosterol biosynthesis), leading to ergosterol depletion and disruption of fungal cell membrane integrity[1][2] - Terpenoid bodies (hypermorphic liposomes containing terpenes) serve as a delivery system for fenteconazole nitrate, which, compared to free drug and conventional formulations, enhances vaginal mucosal permeability, prolongs local drug retention time, and improves antifungal efficacy[1] - A 1-gram fenteconazole nitrate suppository formulation administered in a very short two-day course improves patient compliance and has efficacy comparable to or better than longer courses in treating vulvovaginal candidiasis[2] |
| Molecular Formula |
C24H20CL2N2OS.HNO3
|
|
|---|---|---|
| Molecular Weight |
518.41
|
|
| Exact Mass |
517.062
|
|
| Elemental Analysis |
C, 55.61; H, 4.08; Cl, 13.68; N, 8.11; O, 12.34; S, 6.18
|
|
| CAS # |
73151-29-8
|
|
| Related CAS # |
72479-26-6;73151-29-8 (nitrate);
|
|
| PubChem CID |
51754
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.26g/cm3
|
|
| Boiling Point |
637.2ºC at 760 mmHg
|
|
| Melting Point |
135-137ºC
|
|
| Flash Point |
339.2ºC
|
|
| Index of Refraction |
1.632
|
|
| LogP |
7.474
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
6
|
|
| Rotatable Bond Count |
8
|
|
| Heavy Atom Count |
34
|
|
| Complexity |
524
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
ClC1C([H])=C(C([H])=C([H])C=1C([H])(C([H])([H])N1C([H])=NC([H])=C1[H])OC([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])SC1C([H])=C([H])C([H])=C([H])C=1[H])Cl.O([H])[N+](=O)[O-]
|
|
| InChi Key |
MXQVMHNIUUXDQW-UHFFFAOYSA-O
|
|
| InChi Code |
InChI=1S/C24H20Cl2N2OS.NO3/c25-19-8-11-22(23(26)14-19)24(15-28-13-12-27-17-28)29-16-18-6-9-21(10-7-18)30-20-4-2-1-3-5-20;2-1(3)4/h1-14,17,24H,15-16H2;/q;-1/p+1
|
|
| Chemical Name |
1-(2-(2,4-dichlorophenyl)-2-((4-(phenylthio)benzyl)oxy)ethyl)-1H-imidazol-3-ium nitrate
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100~104 mg/mL (192.90~ 200.61 mM )
Ethanol : ~2 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.5 mg/mL (4.82 mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9290 mL | 9.6449 mL | 19.2898 mL | |
| 5 mM | 0.3858 mL | 1.9290 mL | 3.8580 mL | |
| 10 mM | 0.1929 mL | 0.9645 mL | 1.9290 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA